Ideal Power Inc. — FY2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone fourth-quarter report; quarterly results are not clearly provided in the filing text.
Business context
Ideal Power is shifting from power conversion systems using its PPSA technology to developing and commercializing its B-TRAN bidirectional solid-state switch. On January 2, 2019, the board approved suspending further PPSA development and sales while seeking a buyer for that business and its technology. PPSA is reported as discontinued operations and held for sale. B-TRAN remains under development, with a proposed commercialization model based primarily on licensing.
Key financial metrics
| Metric | FY2018 | FY2017 |
|---|---|---|
| Continuing-operations revenue | $0 | $0 |
| Discontinued-operations product revenue | $1.625 million | $1.212 million |
| Research and development expense, continuing operations | $871,742 | $715,841 |
| General and administrative expense, continuing operations | $3.440 million | $3.512 million |
| Loss from continuing operations | $4.272 million | $4.210 million |
| Loss from discontinued operations | $3.633 million | $6.225 million |
| Net loss | $7.905 million | $10.435 million |
| Net loss per share | $0.56 | $0.79 |
| Operating cash outflow, including discontinued operations | $6.546 million | $7.416 million |
| Cash and cash equivalents at year-end | $3.258 million | $10.022 million |
| Net working capital at year-end | $3.549 million | Not stated |
FY2018 discontinued operations had product costs of $1.969 million against $1.625 million of revenue, as well as $2.095 million of R&D, $774,500 of sales and marketing, and a $360,000 impairment charge. No continuing-operations gross margin is applicable because there was no continuing revenue. The company reported no long-term debt; total long-term liabilities were $428,163, primarily related to a licensing agreement. Total liabilities were $1.568 million and stockholders’ equity was $4.598 million at year-end.
Changes versus FY2017
- Net loss narrowed by about $2.530 million, chiefly because discontinued-operations losses fell; continuing-operations loss increased slightly.
- Discontinued-operations loss declined 42%, reflecting cost reductions and less product-development activity, partly offset by the $360,000 impairment.
- R&D expense rose 22%, mainly from personnel and development costs. G&A expense declined 2%.
- Operating cash outflow improved by about $869,000, but year-end cash fell by $6.764 million. FY2017 included $13.657 million in net proceeds from a private placement; FY2018 had no comparable equity financing.
Outlook, risks and unusual items
- Management expects higher R&D expense in 2019 as the company focuses on B-TRAN, lower G&A expense from reduced staffing and other cost cuts, and lower operating cash outflows. These are expectations, not formal financial guidance.
- The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management stated that additional third-party capital would be needed to fund at least the next 12 months; MD&A also estimated a need to raise capital within 12–15 months of the report’s issuance. Financing availability and terms are uncertain.
- B-TRAN is not commercialized and there is no assurance it will meet development milestones, achieve customer adoption, generate licensing revenue, or become profitable. Development depends on fabrication partners and successful two-sided wafer processing.
- The company reported FY2018 prototype tests showing electrical losses below 40% of those of conventional power switches. This is an early development result, not evidence of commercial-scale performance.
- The PPSA sale is uncertain. The held-for-sale assets were written down by $360,000 to estimated net proceeds; failure or delay in selling the division could consume additional cash and distract management.
- Subsequent events include a January 2019 reduction-in-force with $92,600 in termination benefits, a February conversion of 708,430 preferred shares into common shares, and a Nasdaq extension through September 3, 2019 to regain the $1 minimum bid-price requirement, with a reverse split identified as a possible remedy.
- Legal recoveries improved FY2018 results: the company received a $328,451 arbitration award and $203,121 related to a former customer’s overdue receivable, including late fees and partial legal-cost recovery.
Important facts for investors to verify
- Current cash runway, expected spending, and the amount, timing, and terms of any required financing.
- Progress on B-TRAN engineering samples, fabrication yields, independent testing, partner evaluations, and potential licensing arrangements.
- Status, expected proceeds, and timing of the PPSA division and technology sale.
- Whether the company regained Nasdaq bid-price compliance by September 3, 2019, and whether any reverse split or other listing action occurred.
- How the post-year-end workforce reduction and cost-cutting plans affected ongoing expenses and development capacity.